350 related articles for article (PubMed ID: 16331493)
1. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.
Wang H; Wang Z; Wang S; Li M; Nan L; Rhie JK; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):255-60. PubMed ID: 15868148
[TBL] [Abstract][Full Text] [Related]
4. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
7. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
8. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Orsolic N; Golemovic M; Quintás-Cardama A; Scappini B; Manshouri T; Chandra J; Basic I; Giles F; Kantarjian H; Verstovsek S
Cancer Sci; 2006 Sep; 97(9):952-60. PubMed ID: 16822295
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
10. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
14. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Jia L; Coward LC; Kerstner-Wood CD; Cork RL; Gorman GS; Noker PE; Kitada S; Pellecchia M; Reed JC
Cancer Chemother Pharmacol; 2008 Jan; 61(1):63-73. PubMed ID: 17356822
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis identifies oxidative stress induction by adaphostin.
Stockwin LH; Bumke MA; Yu SX; Webb SP; Collins JR; Hollingshead MG; Newton DL
Clin Cancer Res; 2007 Jun; 13(12):3667-81. PubMed ID: 17575232
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Tourn E; Haenen GR; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Nov; 52(5):371-6. PubMed ID: 12898182
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
Lukka PB; Paxton JW; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378
[TBL] [Abstract][Full Text] [Related]
19. Disposition of abouthiouzine: a novel antihyperthyroid drug.
Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128).
Newman RA; Fuentes A; Covey JM; Benvenuto JA
Drug Metab Dispos; 1994; 22(3):428-32. PubMed ID: 8070319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]